Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

SHA: 688566

    • Home
    • SHA: 688566
Company Drug

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Fineline Cube Oct 31, 2025

Jiangsu Jebel Pharma Co., Ltd. (SHA: 688566) today announced that its novel antidepressant JJH201501, developed...

Company Drug

Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC

Fineline Cube Jul 11, 2025

China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...

Company Deals

Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market

Fineline Cube Jun 25, 2024

Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful...

Recent updates

  • InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
  • Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
  • GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
  • B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
  • OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.